At a time when some sustainability themes face headwinds, water offers stability. While funding for some “green” initiatives is at risk of being reduced, water will remain a priority as it is an essential resource with no substitute. Regardless of corporate “Water Positive” commitments, businesses need reliable supply for their operations. And ensuring a secure supply is paramount for countries’ citizens and industry; water infrastructure will continue to receive investment. We note the allocation of €500 billion for infrastructure in Germany’s historic spending bill, some of which is sure to go to the nation’s water woes. Trump is also wading in; part of the appeal of Canada as a 51st state is its abundance of freshwater.
Across the globe, freshwater supply is already challenged. Projections by the Global Commission on the Economics of Water show demand will outpace supply by 40% by 2030 (that is just five years away!). The map below shows current annual water risk. Unfortunately, demand is set to increase: The rapid expansion of AI use and data centres is adding pressures and the reshoring of industry in the wake of peak globalization will further compound the problem. Moreover, it is not just a question of quantity, but also quality – note the new PFAS regulations introduced in the U.S. last year.

Source: Aqueduct Water Risk Atlas
These challenges create a broad set of investment opportunities across our water theme, from utilities to advanced water technologies. The SMS water theme has performed relatively well over the past three years (see table below) and shown resilience in the turmoil of the first quarter of 2025 – up +3.10% versus the global index -0.15% year-to-date.
We have written several notes on water, notably on smart water technologies (The Digital Water Revolution, June 17, 2021), and innovations in water treatment (Drowning in Denial, March 30, 2023). In this note, we focus our attention on a water sub-sector which is very attractive in the current market environment where economic and policy uncertainty is rising: water utilities.
Stable Currents: The Water Utility Leaders
As discussed in our latest quarterly macro outlook: Macro Meets Sustainability: Outlook for Q2 2025 and Beyond (March 13, 2025), sectors with defensive characteristics are attractive in the current economic context. Water utility companies fit this description, offering stable cash flows and strong dividends along with a key advantage: the ability to pass through infrastructure investments and rising costs. This creates a well-timed investment opportunity as capex on upgrades will translate to higher rates in the future.
Publicly traded water utility companies with a sizable market cap (at least 1 billion USD) are concentrated in the United States, the UK and Brazil. Other utilities operating in the water sector do exist but have energy, or some other segment, as their primary business. For the purpose of this note, we exclude these energy-water utilities from our analysis. Companies with majority state ownership are also excluded.
Sink or Swim: Water Utilities’ Debt
Debt is an important consideration for water utility companies as it is used to finance infrastructure improvements. Of course, this means investors should be mindful of the interest rate environment when assessing opportunities. Our economic outlook for a stagflation scenario (lower growth, higher inflation) means that interest rates are likely to be less aggressive than in 2022; moreover, higher inflation tends to be passed through via regulated utility rate increases, further enhancing the appeal of these investments.
SABESEP has the lowest debt-to-equity of all the companies in our table. Prior to July 2024, the Sao Paulo State Government had 50% ownership in SABESAP facilitating access to low interest public financing. Sao Paolo State has since reduced its stake to 18%. UK water utilities have much higher Debt-to-Equity ratios, partly due to their national regulatory framework that encourages more borrowing to finance infrastructure investments. This has led to issues for UK water utilities; most notable is the debt scandal embroiling private company Thames Water. In contrast, rate setting frameworks in the U.S. tend to be more conservative, typically using a “cost-of-service” model that sets rates based on incurred costs. This difference is also reflected in the higher betas of UK water companies. SABESP also has higher beta versus American utilities, reflecting the risks of emerging market volatility. It is also subject to a more complex rate-setting mechanism. Given these differences, we prefer the stability of American water utilities in the current context.
Open the Taps: Growth Beyond Rate Increases
Aside from rate increases, water utilities can achieve growth through M&A and enrolling new customers. The U.S. is a bigger prospective market for M&A deals since their water system remains fragmented with many operators in regional monopolies. American Water Works is the standout for its M&A activity. As the largest player, it has been the most active in pursuing acquisitions by far.
M&A activity among UK companies is lower. Only Pennon Group and Severn Trent had any acquisitions in the last five years, totalling four and three, respectively. The single deal for SABESP in the same period was a minority stake.
American Water Works is also the most geographically diverse. Since rates are regulated at the state level, this diversification is advantageous in that the company is not subject to one single rate decision. SJW only operates in four states but offers exposure to Texas, one of the fastest growing states in terms of population. The majority of regulated revenues for California Water Services and American States Water co. are highly concentrated in California.
The Infrastructure Imperative
Investing in infrastructure upgrades is essential to ensuring supply, addressing inefficiencies like leaks and improving water and wastewater treatment. Due to aging infrastructure, significant capital investments are expected. The American Society of Civil Engineers’ latest infrastructure report card grades the U.S. infrastructure for Drinking Water, Stormwater and Wastewater as C, D and D+ respectively. The report also projects a persistent funding gap over the next ten years, which could prompt federal and state initiatives. Existing support from the Infrastructure Investment and Jobs Act will expire in 2026.
For their part, American water utilities are already announcing increases in their capital expenditure compared to previous years. The chart below shows the American water utility companies with the highest and lowest FWD P/E ratios; this rank has generally persisted throughout the presented history. While valuations for these companies remain elevated, they reflect expectations for growth that will be driven by these infrastructure investments, which will be passed on to customers through rate increases. Note that rate adjustments must be approved by state level regulatory boards; but the regulatory backdrop looks favorable. Each of the companies touted revenue increases from rate case outcomes in 2024 with positive outlooks for decisions to come.
The opening months of 2025 have seen market swings, volatility spikes and ripening conditions for a bear market. Politics and geopolitics have taken central stage and will drive investment outcomes for sustainability portfolios for the remainder of the year and beyond. In this installment of our quarterly update on Macro Meets Sustainability, we argue that despite the noise emanating from Washington, in terms of concrete policy action, the euro area’s recent (fiscal) policy moves are the more significant market driver. We also underscore our view, outlined in several recent notes, that global inflation risks are rising while economic growth momentum is slowing, creating a stagflationary environment. The implication is that the rotation to defensive sectors and to euro area stocks has further to go.
U.S. Noise and Euro Area Action
Contrary to mainstream media and financial pundits, our observation is that U.S. policy changes have underwhelmed so far in 2025; the biggest surprises and significant policy action have occurred in the euro area:
In the U.S., the daily headlines of federal firings, deportations, and tariff threats means the Trump’s administration occupies most of the space. However, what has actually been accomplished on any of these fronts?
In terms of DOGE, it’s difficult to know exactly how many layoffs have taken place but estimates of federal job separations in February were about 60 000, an insignificant number in an economy that employs over 160 million people. To be sure, the immeasurable loss of experience in federal institutions is lamentable and sows the seeds for challenges in the future. However, the impact on economic activity in the near term is likely to be very low.
Meanwhile, although much has been threatened, tariffs imposed on trading partners are so far only slightly more punitive than what occurred during Trump’s first term, which had little impact on overall global activity. The range of possibilities on what comes next is extremely wide, but a pattern has emerged whereby U.S. tariff barks have been worse than the bites.
Finally, while we continue to believe that over time, the level of illegal (and legal) immigration to the U.S. will be aggressively curbed, ICE is operating with the same budget that it had on Jan. 19. This suggests that it is highly unlikely that the government’s targets of over 1000 arrests per day are even close to being met; only the most migrant worker-dependent sectors like agriculture will feel the near-term impacts of current U.S. immigration policy.
In contrast, the threats and proclamations of the Trump administration have been sufficient to shake European policymakers out of their torpor as they seem to be working with renewed vigor. On Tuesday, the German parliament approved Chancellor Merz’s plan to spend up to €1 trillion in coming years on infrastructure and defense. EUR500B is earmarked for infrastructure and green initiatives. This massive spending deal means that just the infrastructure fund alone adds over 1% to GDP over the next decade, even without applying a fiscal multiplier (i.e. positive knock-on effect). Added on to this is the announcement in early March by Ursula von der Leyen that the new “ReArm Europe” investment plan will unlock a €150 billion loan scheme to help Member States invest in key military capabilities.
Our key takeaway is that while investors must stay attuned to possible impacts on global growth and financial markets stemming from the U.S., so far in 2025, realized policy activity has been more significant in Europe than in North America. This provides at least a partial foundation for why we expect the outperformance of euro area equities to continue for the next few quarters.
It’s Still The Economy, Stupid
Although it is well known that financial markets respond poorly to economic and policy uncertainty, the current instability in risk assets can not be solely attributed to uncertainty arising from Trump’s leadership style (described as “flooding the zone”). Indeed, U.S. economic growth was losing momentum well before Trump moved into the White House, and earnings expectations were also ratcheting down prior to Trump’s inauguration.
One very well-known and favored indicator is the economic surprise index, which tracks the strength of incoming data relative to expectations. In the U.S., the economic surprise index peaked in November and is now in negative territory, meaning that data is weaker than forecasted. In the euro area the indicator displays the opposite trend (data is surprising to the upside). The chart below shows the surprise indicator for the U.S.
Of course, the above analysis is only useful in that it helps explain what has already happened. However, in the U.S. there is likely to be more months of negative surprises before an inflection point is reached because economic surprise indices tend to be mean-reverting and swing in regular patterns – it takes time for expectations adjust to economic reality.
Beyond this, there are three reasons we expect that the environment for euro area stocks will support continued performance for the next few quarters:
1. More room for fiscal and monetary support outside of the U.S.: though it’s unknown to what extent Trump’s ambitions will translate into action, the direction of travel on virtually all of his stated plans translates to: more inflation and less growth in the near-term. We have written about the inflationary impulse in previous notes (for example, see “Food Fight: Policy’s Effect on Food Producers & Inflation”, February 13, 2025 and “Playing the Trump Card”, November 21, 2024) and the Fed’s updated FOMC projections yesterday are very much in line with our view. In plain language, Federal Reserve Chair Jay Powell acknowledged that further progress on inflation was likely to be “delayed for the time being”. The corollary is that the U.S. Federal Reserve may not have the leeway to loosen monetary policy given its 2% inflation target. Indeed, the OECD recently updated its inflation forecasts. With assumptions about future tariffs, the inflationary impact is strongest in North America.
As discussed above, Germany is already forging a new path for fiscal policy and we expect other countries with the fiscal space will follow suit, whether it be in the form of relief to businesses to offset the tariff shock (as announced in Canada) or to raise defense spending.
2. Euro area sustainability stocks still trade at a discount relative to their U.S. counterparts. Euro area stocks have been comparatively cheap for years, but the recent divergence in price performance has done little to correct this gap. This is also true for the Sustainable Market Strategies’ sustainability universe. The average forward P/E for euro area stocks in our universe is 18 compared to 29 for the U.S.
3. The U.S. has Mag 7, but the euro area has defense stocks. The U.S. equity outperformance streak in 2023-2024 was without a doubt characterized by a strong tailwind emanating from the Magnificent 7 stocks and a bubble for everything artificial intelligence. China’s Deepseek helped to burst the bubble earlier this year. In contrast, we believe the prime candidate for a future “bubble” sector in the euro area is still in full swing. As we wrote in a recent note, “The European Defense Offensive: From Peace Dividend to War Premium”, the European Commission has recently unveiled an ambitious plan to mobilize approximately $840 billion to bolster the EU’s collective defense capabilities. There is a clear bias for European countries to invest in European defense companies, and despite the near parabolic rise in the biggest defense names, there are still several companies with moderate valuations that satisfy our strict sustainability criteria. But even for investors that do not wish to be long defense companies, the “euphoria” surrounding this sector will likely lift related stocks, especially euro area industrials. On this basis, just as the U.S. tech sector is becoming a drag on broad U.S. equity indices, the bull market in the euro area defense sector could boost European indices.
In sum, despite the fact that geopolitical tensions are emanating from the U.S. and onto the rest of the world, we expect that euro area stocks will continue to outperform.
Defensive Rotation Is Justified
Stocks in defensive sectors like health care, consumer staples and utilities outperform when uncertainty is high and/or when recession risks are elevated because it is difficult to cut back on essential spending.
From a sustainability standpoint these sectors are often appealing because underlying products and services can create positive impact on individual lives. In recent weeks, we have written notes on two of these critical sectors – health care and food staples – and how sustainability investors should maintain a postive bias in this space despite needing to navigate the ongoing policy crosscurrents. Developments over the past few weeks only serve to strengthen our conviction. Interestingly, euro area stock markets tend to have a greater exposure to defensive sectors (healthcare is about 16% in the Eurostoxx 600 index versus 10% in the S&P 500), which also helps to explain some of the European outperformance in recent weeks.
In times of economic uncertainty, investors turn to defensive sectors like healthcare. After all, people need medical care regardless of economic conditions.
But like almost all sectors in financial markets, healthcare is not immune to the volatility emanating from the new U.S. administration. Investors seeking stability in this impactful sector must navigate Trump’s desire to shakeup the U.S. healthcare system and Make America Healthy Again. Admittedly, this is a tall order since deciphering the signal from the noise during the Trump regime is difficult. However, of the eleven executive orders addressing aspects of U.S. health care, we believe there are three key areas to focus on:
- A desire to improve drug price transparency; An executive order for clear, accurate and actionable healthcare pricing information signed on February 25th signals a potential shakeup for a system that has long thrived on opacity. Though it lacks specific details, simply tasking relevant agencies – Health and human services, Treasury and Labor – with expanding enforcement of price initiatives introduced in Trump’s first term, the order shows that price transparency remains a priority.
- A desire to reduce the breadth of government-sponsored coverage: An executive order reversing Biden era efforts to expand health coverage was signed on January 20th. It amounts to making it more difficult for citizens to access coverage. Moreover, the budget passed in the House on February 25th calls for $880 billion in savings from the committee overseeing the spending of these plans. Achieving the desired cost reductions looks virtually impossible without cutting funding.
- A desire to reduce the number of Americans suffering from chronic illnesses: An executive order on February 13th was signed to establish a new “Make America Health Again” commission. Its stated aim is to combat the “rising rates of mental health disorders, obesity, diabetes, and other chronic diseases” with emphasis on children.
In today’s Note, we consider these three political desires and how they affect the healthcare sector. We focus on drug producers, equipment makers and health insurance providers as these are the biggest categories within the healthcare sector and also the most at risk from policy changes. Investors looking to increase exposure to the health care sector should focus on companies with one or more of the following characteristics:
- At lower risk from drug pricing negotiations.
- A high percentage of production occurring domestically (to lower the risk of negative tariff implications).
- High exposure to chronic illnesses rather than communicable diseases.
A. Drug Production: Favor “Small” Pharma, Chronic Disease Specialists
The appointment of Robert F. Kennedy Jr, as well as an executive order on February 13th, Establishing the President’s Make America Healthy Again Commission, clearly suggests the direction of policy travel: addressing the rising number of Americans – especially children – affected by chronic illnesses is a desired priority. After all, 90% of the U.S.’ $4.5 trillion in annual health care expenditures are for people with chronic and mental health conditions.
Concurrently, one of the few areas of the Inflation Reduction Act that has stayed in place under the Trump administration is the Medicare Drug Price Negotiation Program. The program was established to allow the Department of Health and Human Services (HHS) to negotiate maximum fair prices for certain high expenditure drugs and biological products. There are currently 25 medications that are subject to price negotiation with another 35 that will come to the negotiating table in 2028 and 2029 (a timeline is provided below); all were chosen because they are among the prescription drugs for which Medicare spends the most.

The first ten drugs identified for price negotiation have already settled: new prices come into effect in 2026 and the stock prices of companies affected have already digested the news. The negotiated price for the other fifteen drugs will only be announced in November 2025. Seventeen companies produce these 25 drugs, with Novo Nordisk, GSK and Astellas Pharma having the highest Medicare revenue from drugs selected for price negotiation. However, the financial impact on each company will ultimately depend on the extent of the negotiated price reductions.
Unsurprisingly, the list of drugs subject to price negotiations features many of the largest pharmaceutical companies. In the table below, we highlight the top five players by market share in each of the five most common chronic illnesses. Note that while for some illnesses like cancer and Alzheimer’s disease, there is a more diversified market (the top five players account for less than half of total market share), for other diseases (arthritis, diabetes) only a handful of companies dominate accounting for over 75% of the total market shared.
Interestingly, the table shows just how big “big pharma” really is. Companies like Pfizer and Johnson and Johnson are among the top players in not just one, but often two or three chronic illness medications. Moreover, they often compete in many other (non-chronic disease) markets; 40% of Pfizer’s revenues are derived from infectious disease medications, and over 20% of Johnon & Johnson revenues are from vaccines.
One could argue that the diversified nature of big pharma’s activities means these companies are well protected from a specific risk or disruption in any one pharmaceutical line. We believe that in the current environment, the opposite is true: a government set on bringing down prices will continue to target the biggest players first.
Therefore, when seeking out defensive health care companies with exposure to chronic illness remedies, we look for:
- Companies with at least 1 billion USD market cap.
- Companies that are relatively concentrated within a specific illness/market, with at least 60% of revenues generated from one industry (e.g. oncology).
- Companies that are free from controversy.
By applying the above criteria, we find twelve companies in four chronic disease segments (cardiovascular, oncology, endocrinology, and neurology); we expect that ongoing drug price negotiations and President Trump’s push for greater transparency in pharmaceutical price setting will foster a more competitive price environment for smaller companies. These players also have potential as acquisition targets by larger pharmaceutical companies.
Looking at financials for these companies, we favor United Therapeutics (UTHR US), Ipsen (IPN PA) and Neurocrine Biosciences (NBIX US).
United Therapeutics is the only company identified in cardiovascular drugs. The company is specialized in drugs treating hypertension. It boasts strong margins, sales growth and a fair valuation. Despite record revenues in 2024, a slight miss on latest earnings report sent the stock price lower in late February – presenting a compelling entry point.
From the oncology segment, Ipsen is appealing: in addition to having over 70% of its revenue generated from cancer treatments, its remaining revenue sources also stem from non-communicable disease treatments (neurology medications, 19% and OTC drugs, 8%). The company’s relatively lower growth and margin profile suggest a potentially more stable investment than high-growth biotech plays. We like it for this and the associated low beta. Alternatively, the U.S. oncology company Exelixis, demonstrates higher sales growth and a stronger margin while maintaining a low beta, making it a more dynamic alternative within the space.
Within the neurology drugmakers, Neurocrine Biosciences has strong sales growth and profitability, at a reasonable valuation, with lower debt than some of its peers.
B. Healthcare Insurance: Avoid the Giants
The major U.S. health insurance providers, aka “Big Health”, are also at risk from policy efforts to crack down on healthcare costs. Their vertically integrated business models, encompassing Pharmacy Benefit Management Services (PBMs), patient care, drug distribution and other health care services, make them particularly vulnerable to systemic changes.
Cuts to Medicare and Medicaid could reduce revenues from government-managed plans – especially Medicaid, where low-income individuals are unlikely to convert to private plans. Moreover, price transparency reforms threaten profits in patient care, drug sales and PBMs. PBMs have been directly called out by Trump for their role in higher drug prices, he has threatened to “knock them out.” UnitedHealth, Cigna, CVS and Elevance account for virtually all (99.8%) of the PBM market according to FactSet data. While cuts to government-supported health coverage will face some resistance, broad dissatisfaction with the U.S. healthcare system means efforts to curb high prices will have bipartisan support, meaning there is greater likelihood that those initiatives pass.
There are some health service providers already offering an alternative approach. So-called “value-based” healthcare incentivizes patient outcomes over volume of tests, prioritizing quality over quantity and assessing value through the cost of treatment for the achieved health outcome. These companies have a competitive edge that puts them ahead of potential regulatory changes. Privia Health (PRVA US) is one such company. It partners with physicians, using technology and offering administrative support to improve patient experience and reduce unnecessary costs. Other value-based insurers like Alignment Healthcare and Clover (both also over US$1 billion in market cap) have had strong stock performance but have reported negative earnings in the past few years.
C. Healthcare Equipment: What Domestic Production?
Medical equipment makers face limited risks from healthcare policy changes but nonetheless remain exposed to trade tensions and geopolitical shifts: U.S. tariffs could increase costs for multinational manufacturers, creating advantages for domestic producers. Additionally, retaliation to tariffs, like China’s recent ban on Illumina’s gene sequencers, highlights the possibility of tit-for-tat trade wars in the sector.
Readers of our work know that healthcare equipment, especially those focused on an aging population, is one of our favored health care sub-sectors (for example, “Grandpa’s Gadgets: Healthcare Devices for Increased Longevity”, June 22, 2024). Normally, companies that specialize in joint replacement and orthopedic products, vision and hearing solutions as well as diagnostics and treatments for chronic illnesses are excellent outperformance candidates during bear markets and the recent correction is no exception, as shown in the chart below. Unfortunately, however, the trade backdrop now obfuscates the outlook.
The main lobby group for medical device makers, Advamed has already sought an exemption from Trump’s tariffs, saying that tariffs will devastate the industry. Indeed, about 70% of U.S. marketed medical devices are manufactured solely outside of the U.S., making the industry highly reliant on foreign production.
Whether the industry can negotiate a tariff carve-out is an open question, although there is a positive precedent. In 2018, Advamed effectively lobbied the Trump government and was able to severely limit the number of medical devices that were subjected to Trump’s China tariffs at that time.
In the table below, we provide a shortlist of medical device manufacturers that have strong tailwinds to their businesses, though long positions should only be activated if tariff carve-outs occur. Note that compared to pharmaceutical companies, equipment makers on average exhibit higher valuations and relatively lower beta. In particular, Edwards Lifesciences, Abbott Laboratories and Danaher stand out, combining high R&D investment, strong profitability, and solid sales growth with manageable debt.
Almost two years ago, we wrote what was then a controversial note about the role of defense companies in sustainable investing (see Defending the indefensible? An ESG perspective, May 11, 2023). Fast-forward to today, and this topic has become much more accepted, though still not quite mainstream.
In our previous note, we argued that a subset of the defense sector—specifically what we called the “European Defense Specialists” as opposed to the “American Defense Primes“—should be considered by sustainability-minded investors. Our thesis was based on two key factors: European defense companies demonstrate significantly stronger governance than their American counterparts, and European defense expenditures were poised for massive increases. This strategy has performed exceptionally well, with the SMS European Defense Specialists Basket dramatically outperforming both American Defense Primes and the S&P 500 since our May 2023 publication.
The End of Pax Americana
Recent geopolitical developments, including the Oval Office showdown between Zelenskyy, Trump, and Vance that led to the immediate freezing of all U.S. military support to Ukraine, only strengthen our thesis. What we're witnessing is essentially the end of the post-Cold War "peace dividend" era. For decades, European nations comfortably operated under the Pax Americana security umbrella, maintaining modest defense budgets while focusing on social spending and economic integration. This convenient arrangement—Europeans handling "soft power" (diplomatic influence, cultural appeal, economic incentives, and humanitarian aid) while America provided "hard power" (military might and security guarantees)—is now being fundamentally reconsidered.
Prior to 2022, only the UK, Poland, and France among major European powers were approaching or exceeding NATO's 2% target. Faced with the stark realization of their strategic vulnerability, European nations have been forced to step up.
The ReArm Europe Initiative
Earlier this week, the European Commission unveiled an ambitious plan to mobilize approximately $840 billion to bolster the EU's collective defense capabilities. This plan, dubbed "ReArm Europe," aims to provide European countries with the financial resources to modernize their armies, enhance their collective defense systems, and increase support for Ukraine.
The initiative includes a new fund worth more than $150 billion to support EU members' defense investments, while simultaneously relaxing the bloc's debt rules (effectively the "debt brake" to allow for higher defense spending). Additionally, the EU plans to leverage profits from sanctioned Russian assets (approximately $200 billion held in Europe) to help finance military assistance to Ukraine. While some, like President Zelenskyy, have floated the idea to seize and redirect these $200 billion towards security, France's finance minister has expressed opposition to this mechanism as these are Russian central bank assets and are protected by international banking agreements.
The Global Defense Spending Shift
The chart below illustrates the dramatic shift in the global balance of defense spending from 2011 to 2023. The United States has experienced a steady decline in its proportion of global defense spending, dropping from over 50% in 2011 to just 37.7% by 2023. Even in absolute terms (using constant 2022 USD), U.S. spending fell from nearly $1 trillion in 2010 to approximately $880 billion in 2023—a reduction of 12%.
Conversely, Europe (including the UK) has demonstrated remarkable growth, particularly in recent years. From 2011 to 2021, European defense spending as a percentage of the global total increased modestly from 17.9% to 19.8%. However, 2022-2023 showed dramatic acceleration, with Europe's share jumping to 24.4% by 2023—a clear response to the radically altered security environment following Russia's invasion of Ukraine. With the implementation of the ReArm Europe initiative, Europe's defense expenditures could represent over one-third of global defense spending within the next few years.
A More Sophisticated Screening Approach
These developments reinforce our conviction to focus on European Defense Specialists rather than American Defense Primes. We've expanded our analysis to include several additional critical factors:
- Allied Revenue Alignment: We assess the proportion of revenue derived from NATO and other allied nations, aiming to minimize exposure to companies with significant revenues from potentially misaligned or authoritarian regimes.
- Government Independence: We evaluate the percentage of each company owned by governments. Generally, we favor greater independence from government control to maximize innovation potential and governance quality.
- R&D Investment: We analyze R&D expenditure as a percentage of revenue. Modern warfare demands constant technological advancement—companies that fail to innovate today will be irrelevant tomorrow.
- Strategic Defense Orientation: We focus on companies specializing in technologies and systems designed primarily for defensive purposes—such as air defense systems, cybersecurity solutions, and intelligence platforms—rather than offensive-oriented activities like armored assault vehicles, strike missiles, and tactical combat systems.
Based on this multi-factor approach, six companies stand out as meeting most of our criteria (highlighted in green in the table above).
Unsurprisingly, all six companies have performed exceptionally well since Russia's invasion of Ukraine three years ago. Even the weakest performer in our selection managed to outperform the S&P 500 by a factor of three. However, the performance disparities within the group are notable and raise a critical question: Can this level of outperformance be sustained?
To assess whether these companies can maintain their momentum or if “laggards” might catch up, we look at forward valuations using 12-month price-to-earnings ratios.
While Saab and Leonardo predictably command higher valuations given their remarkable performance runs, what's truly surprising is that despite their extraordinary performance, their P/E ratios remain below 35x—relatively reasonable for companies experiencing such dramatic growth.
Nevertheless, considering the parabolic trajectories of Leonardo and Saab, a prudent alternative strategy would be to shift focus toward the "second wave" of European Defense Specialists. These companies—Thales SA (HO-FR), BAE Systems plc (BA-GB), Indra Sistemas SA (IDR-ES), and QinetiQ Group plc (QQ-GB)—stand to benefit substantially from the recently announced ReArm Europe program and have yet to experience a dramatic valuation expansion.
The election of Donald Trump and the resurgence of European populist parties does not augur well for global policy regarding environmental challenges. Trump already pulled the U.S. out of the Paris 2015 Climate Accord (again) and started rolling back most of Biden’s environmental regulations of the past four years. In Europe, the European Commission watered down its ambition as it looks to impose the Carbon Border Adjustment Mechanism (CBAM, see our note “Carbon Protectionism: Winners and Losers under EU’s Carbon Border Plan”, July 25, 2024). In this context, some investors and carbon market participants are already asking whether regulated carbon markets – both in Europe and in North America – are poised to end.
Many speculators – mostly financial market participants, as opposed to regulated entities – have indeed left the market these past few months looking for better return opportunities elsewhere. Looking at recent carbon market auction data from the California Air Resource Board (CARB), one sees that the share of “voluntarily associated bidding entities” (i.e. speculators) was lower at the end of 2024 if compared to 2022-2023 averages. This has pressured carbon prices lower.

Why is the WCI Carbon Markets so Attractive?
While market sentiment and recent price-action of global regulated carbon markets have been negative lately, carbon market fundamentals remain strong – which is mostly true in North America. Interestingly, EU ETS market has been less affected by the current political environment in the U.S. and Canada than its WCI counterpart, which could explain the relative resilience in the price of EU emission allowances vis-à-vis those traded in the WCI market. That being said, current woes of the German industrial sector – a key player in EU emissions – could also mean that there will be less upwards price pressure on EUAs in in the coming years vis-à-vis WCI allowances.
This is why we think that the most interesting investment opportunities can be currently found in the Québec-California market. First, North American carbon markets are trading close to their regulated floor price. To this end, the most recent WCI auction (on February 19th) shows that the current price of $29.27 (a $2.64 decrease from the previous auction in November 2024) is just $3.40 above the 2025 Reserve Price.
Second, Québec and California issued fairly ambitious and restrictive emission reduction targets in the Fall of 2024 (good for carbon prices) for the period going up to 2030. While market rules for the post-2030 period have been delayed because of wildfires and a tough political environment (tariffs on Québec industrial exports), both Québec and California should publish them later this year, which should provide support for higher prices going forward.
Third, states like Washington – who are toying with the idea of linking their market with the WCI – are not afraid to buck the current political trend and press ahead with their climate ambitions.
Fourth, while the price of carbon – and its “social acceptability” – has been negatively affected by the current political context, many of the U.S. and Europe’s “Big Businesses” – most of them being regulated entities – are re-iterating their preference for keeping a price on carbon.
Finally, one could think that energy demand coming from AI data usage added to the reshoring of industrial activities in North America in many sectors required to comply with emission reductions should also put a floor on carbon prices going forward.
Could Populism Kill Carbon Markets?
In theory, both California and Quebec could eliminate their carbon market; in practice they won’t. That’s because those jurisdictions would probably have to repay emission rights holders – or else face a series of costly lawsuits, such as the one initiated under NAFTA’s Chapter 11 by Koch Industries against Government of Ontario in 2020. In that, the idea of repaying emission rights holders for the value of their carbon credits in the current fiscal context seems unfeasible.
After all, carbon markets, both in Europe and North America, have been in operation for more than a decade. For businesses, this means that some regulated industry participants have built a significant vested interest in these markets over time. Companies such as Tesla, which has reaped a USD 10 billion windfall from the sales of its carbon credits since 2017, are still seeing their revenues being bankrolled by the value of their carbon credits.
Turning to governments, many jurisdictions are seeing carbon markets as a precious source of revenue in times of fiscal consolidation. According to the World Bank, the EU and governments of California and Québec have respectively collected USD 160, 21 and 6 billion worth of cumulated fiscal revenue since 2018 through their carbon pricing schemes.
In all, the most likely course of action is that carbon markets are here to stay – even if we could expect them to be somewhat less buoyant than what was expected in 2024 due to current political headwinds. Other risk factors could come from the prevalence of natural disasters such as the recent wildfires in California – which have delayed rule making with regard to carbon market for the post 2030 period - and the fact that elevated carbon prices could be perceived as contributing to higher cost of living for consumers - notably through higher food and energy prices. In Europe more specifically, difficulties in in the industrial sector amid the need to produce more energy domestically (e.g. natural gas, coal) could also reduce policymakers’ appetite to make carbon markets more stringent than what was planned.
The global fertility rate has dropped from around 5 children per female in the 1960’s to a little above 2 now. It is expected to fall below replacement level (2.1) over the next quarter-century. The map below shows where fertility remains above the replacement level: Africa, the Stans (former Russian Republics like Kazakhstan and Uzbekistan plus Afghanistan and Pakistan) and a few countries in South America and elsewhere. It also highlights countries with abnormally low fertility rates like South Korea (under 0.6) and China (1).
The table below lists reasons why fertility rates have fallen so much; from urbanization, lifestyle, policy and biology (contraception improvements, pollution, biological age limits and declining sperm counts). It is difficult to imagine a rapid reversal of those factors.
You Cannot Fake Population Growth
One of the main implications of slower population growth is the impact on real economic growth. Take Scott Bessent’s new 3-3-3 target, which aims for a 3% deficit, 3 million barrel/day of extra US oil production, 3% real GDP growth). Real GDP growth relies on a combination of population growth and productivity growth. In order to achieve 3% real GDP growth, productivity will need to surge to offset the stagnation in the working age population. On the deficit side, an older population is a challenge to spending reductions.
The map below highlights how populations around the world are expected to evolve over the next five years. Most of Europe, Russia, China, Japan and South Korea are expected to have shrinking population whereas other developed economies are expecting limited growth.
Slowing population growth will also be accompanied by a much older population with higher healthcare spending. Considering that in the United States, healthcare expenditures already represent close to 20% of GDP , any productivity improvement in the sector will have to be considered for healthcare to stop growing as a percentage of the economy.
The chart below shows that the peak growth in the elderly population is happening now while overall population growth is slowing. Common discourse implies that we are getting older, but you never hear that we are right in the middle of the peak intensity on a global basis.
A growing elderly population should benefit healthcare companies. The table below highlights companies focused on improved healthcare productivity within our sustainable company investment universe; we expect a growing market for their products and services.
The chart below highlights each company’s stock performance since 2019. As we can see, there have been winners and losers compared to the S&P 500 without a clear trend for the group as a whole.
Senior Spend on Pills
An older population generally requires more health care which puts a strain on public finances and risks triggering intergenerational conflicts; the overwhelming older population will vote to maintain subsidized health services and the young will want better after-tax compensation. The map below illustrates the anticipated evolution of the population for people older than 72; there will be increases in the senior population everywhere in the world over the next five years, except for that little red dot on the map in Timor-Leste where life expectancy is just 69 years old .
The growing number of elderly (72+) will mean increase demand for medication. The table below shows pharmaceutical companies from our sustainable investment universe with solutions for a global population that is living longer.
Just like the performance chart for healthcare productivity companies, there have been winners and losers compared to the index. The two winners, Eli Lilly and Novo Nordisk, have mainly won because of their obesity pills that are not targeting elderly people, at all. As a result, there could be a catch up from the other companies based on growing demand for their products.
Senior Lodging is another segment that will have growing demand. The table below highlights sustainable companies providing senior lodging.
Real estate has suffered from higher interest rates since the pandemic. As we can see, performance for the group has been poor on an absolute and relative basis. Unlike other parts of real estate, like office that has oversupply, senior lodging should have better pricing power in the future.
Smaller Market for the Smallest
On the other hand, the large drop in fertility rate is leading to a totally different picture for children. As the map below shows, most countries will experience a large drop in child populations over the next five years. China and South Korea are among the places where the percentage decline is highest, while increases in the number of children will mainly occur in Africa. Considering the large increases in elderly and the large drop in future workers (children) over the next decade, the incentive to increase immigration, especially for skilled-care workers, should rise.
Companies that focus on products and services for children will face headwinds. The following table shows companies that will need to cope with a globally shrinking children market. Those companies are not negative from a sustainability basis, but we believe investors should be aware that demand for their products could fall.
The stock performance of these companies has been lacklustre other than Build-a-Bear which has boomed.
One of our high-conviction calls for the coming decade is the high likelihood of strong, sustained food inflation. To put it simply, absent a massive productivity surge, it is unlikely that farmers will be able to feed us the low-cost, high caloric diet we have become accustomed to, especially as climate change wreaks havoc with growing seasons and creates the conditions for ever more animal viral outbreaks.
Beyond this base case, a series of policy developments are unfolding in America that hold the potential to disrupt food supply chains. Immigration, tariffs, diminishing government oversight and particular cabinet picks are sparks that have been lit by Trump in 2025 and are on the cusp of unleashing a surge in food prices. Today’s note explores these sparks and what it means for publicly traded food companies.
Implications of Immigration
During his first days in office, Trump took action on immigration as promised during the campaign. The crackdown on inhabitants without legal status is expected to have significant consequences for American farmers. USDA data show that nearly half of the country’s crop farm workers are unauthorized to be in the United States (crop farm workers accounted for 75% of U.S. employment in agriculture in 2023).
Impacts from immigration will also be felt in the livestock sector, which makes up the balance of agricultural employment. Not surprisingly, meat-processor Tyson highlighted immigration policy as a source of uncertainty during the company’s latest earnings call.
The H-2A visa program for farmers to hire foreign agriculture workers temporarily could be seen as a workaround to the deportation issue. But the program’s future under Trump remains unclear; it was mentioned in Project 2025 leading some to anticipate a more challenging approval process. The popularity of these visas (see chart below) underscores the shortage of farm labor in the U.S.; certifications nearly tripled in the last decade. Still, this program is an expensive option - farmers must cover transport, shelter and meal costs for employees in addition to wages that are tied to state minimums.
Investment in automation could be one response to higher labor costs, benefitting companies like Deere, but we remain cautious. Depressed commodity prices, relatively higher interest rates and ongoing tariff uncertainties will make farmers hesitant to spend on equipment upgrades. Subsidies could provide relief (the farm bill has been up for renegotiation since 2023), but increased spending appears challenging under an administration so focused on budget cuts. Furthermore, farm equipment-makers face their own tariff risks: China has targeted farm equipment in its retaliation to U.S. tariffs and last fall Trump threatened a 200% tariff on Deere over the company’s Mexico-based production.
Troubles from Tariffs
On February 4th, Trump imposed a 10% blanket tariff on all products imported from China and is set to impose 25% on Canada and Mexico beginning March 1st. Meanwhile, he also is threatening further duties on European imports. Unless loopholes are created, the food sector will not come out unscathed.
About 15% of total food consumed in the U.S. is imported and the vast majority of this comes from China, Mexico and Canada. In the chart below, we show the impact on CPI food inflation. We assume 15% of the total food basket is slapped with a 25% tariff, while the rest remains at the 2024 annual rate of 2.2%. In this scenario, food price inflation will average close to 6% over the next year, simply due to the tariff effect. With the exception of the COVID period, one has to return to the 1990s to see this level of U.S. food inflation.
Note, this could be a conservative estimate of food inflation, since it does not account for the rising prices of many other input costs also subject to tariffs. For example, the 25% tariff applied to all aluminum imports will affect the cost of packaging (aluminum cans). And as noted in the section below, the cost of fertilizers is a major concern.
As the chart below shows, about one quarter of all fertilizers used in the U.S. are derived from potash. Canada supplies virtually all of the potash used as fertilizer in the U.S. Reliance on foreign sources of nitrogen is considerably less (between 6%–13% of total nitrogen consumption has been imported since 2020). Finally, phosphate imports represent between 6-16% of total phosphate, virtually all of it sourced from Peru and Morocco (countries that are not yet in the crosshairs of Trump).
The bottom line is that Trump’s 25% blanket tariffs will affect about one quarter of all fertilizer used in the U.S., which risks being another important source of inflation to the extent that this input cost is inevitably passed on to end food prices.
Loosey Goosey Regulation (Avian Flu)
Anyone reading American press will know that the price of eggs has become a sore point for many consumers. Avian flu (a.k.a. H5N1 virus) has caused the price of eggs to skyrocket, as 20 million egg-laying chickens have died from the virus in the past quarter.
Unfortunately, it is extremely unlikely that the U.S. H5N1 crisis will end soon. The outbreak is in part a government failure; there is a large consensus view that the USDA did not act swiftly and aggressively enough to stem the virus when it could and it is unlikely a coincidence that other North American jurisdictions have had far more success controlling outbreaks. It is an open question whether the new head of the USDA (Brooke Rollins) will implement policy to stem the animal losses.
Perhaps ironically, some of the biggest American egg producers have seen their profitability and stock price benefit from the outbreak. The two largest publicly traded egg producers are Cal-Maine Foods (CALM US) and Vital Farms (VITL US). Both have seen their stock price skyrocket in the past years, but for sustainability investors looking to get long, only one of these companies merits attention. CALM US has a terrible environmental track record and overall low rankings in CSRHub scores. Moreover, and probably not a coincidence, one reason why the company has been profitable over the past year is because they are a beneficiary of generous H5N1 indemnities: when outbreaks happen, the federal government pays to compensate farmers for the culling of birds and sanitizing of facilities; Cal-Maine has been one of the largest recipients of this aid.
Conversely, VITL has largely avoided avian flu outbreaks over the past three years and is routinely ranked highly for more sustainable practices. Investing in egg stocks at this juncture is a high-risk endeavor, but for investors that like the odds, VITL US is our favored play.
Cabinet Picks Stir the Pot
Although picked for Health and Human Services Secretary, nominee Robert F. Kennedy Jr. (RFK Jr.) will have important implications for food and ag. This role has limited authority over agriculture policy, but does oversee the Food and Drug Administration which regulates food safety. RFK Jr. has been vocal in his criticism of ultra-processed foods and pesticides use. As part of the Make America Healthy Again campaign, RFK Jr. has pledged to take on Big Food.
Weed and pest management has become a key component in agricultural production. Globally, the U.S. is second only to Brazil for total use of pesticides. The charts below show the pesticides use per hectare of farmland (kg/ha).
Over the last decade, pesticide use per unit of land has stabilized in Europe but continued to grow in the United States. This reflects stricter regulations in the EU, but also the dominance of pesticide-intensive crops such as corn and soybeans in America.
Given the environmental and public health risks associated with heavy pesticide use, stronger regulation is not a bad thing. With RFK Jr. selected by a Republican president known for strong-arming, pesticide regulation could gain more conservative support than in the past. However, this would present an enormous hurdle for the agri-science industry (see our note “Agriculture’s Addiction Problem”, September 1, 2022). Curtailing pesticide use would, all things equal, reduce crop yields (food supply) and (once again) put upward pressure on prices.
How to Invest
High food price environments often favor the major food processors like General Mills, Campbell’s, Hershey’s, etc, since they also have the ability to pass on higher input costs in (i.e. have pricing power). Indeed, these companies outperformed the broad market in 2022 when COVID induced supply chain delays caused a spike in food inflation and they also outperformed during the 1970s’ food inflation spikes.
However, as readers of our previous work will know, investing in these companies is no easy task for investors who prioritize sustainability (please see “No Free Lunch: Challenges and Opportunities for Engagement in the Food Supply Chain”, March 7, 2024). Controversies are common (greenwashing, anti-competitive practices) and the holding of subsidiaries that often focus on unhealthy snacks makes these companies often unappealing.
For sustainability investors looking to get long food manufacturing business to position for the likely wave in food price inflation, one approach is to hold a broad basket of the major food companies, and exclude the companies that contribute most to the sweets and snack foods category: Pepsi Co., Mondelez, Hershey, Nestle, Barry Callebaut and Kellanova (the latter is the snack division spun off from Kellogg’s).
Note that in our 2025 Investment Playbook, we highlighted Mondelez and Pepsi as two short candidates based on the premise that they do not fit RFK’s view of healthy food. These companies have already lost value in the run up to his confirmation.
With these exclusions in place, the below table highlights some of the food companies with good sustainability scores that have a lower contribution to the unhealthiest aisles in the grocery store. Of course, to be taken with a grain of salt, while these companies have less revenues from snacks and sweets, some of their products are still deemed unhealthy.
From a financials perspective, Kraft Heinz has higher margins, a lower valuation and positive EPS growth. General Mills also exhibits higher profitability and better growth. Unsurprisingly for consumer staples, all of the companies have forward P/E valuations below the SP500.
The Inevitable Clash
China is the world’s manufacturer, and the United States is its consumer. In the 2000’s, the commercial trade deficit of the United States was larger as a percentage of GDP (6%), it was balanced across many countries and built on the hope that the rise of China would bring new consumers. Obama realized late in his second term that China would not become a consumer, and he timidly pivoted to Asia. In his first term, Trump tried to make a deal with China using sticks (tariffs). Biden maintained those tariffs but used carrots (industrial subsidies for United States production). Trump will now use bigger sticks to reverse China’s manufacturing domination. The chart below highlights the biggest global economic issue of our time between the two largest economies in the world; China produces 5% more than it consumes, and the U.S. consumes 3% more than they produce.
At the top of the following graph, we can see the countries on the target list of the Trump administration’s goal to rebalance production towards the United States. Unsurprisingly, Mexico, Canada and China have been targeted for tariffs for national security reasons even before the required analysis to implement tariffs for economic reasons is completed (the latter should be completed by April 1st). We can expect global tariffs following the economic analysis with special negotiation tariffs for specific countries when opportunities arise.
The chart below describes the items for which the United States has the largest deficits and the largest surplus. The commercial balance is negative for manufactured items and positive for energy and food commodities, as well as high-tech circuits and semi-conductor machinery. The United States will fight hard to keep exporting high-tech circuits and semi-conductors.
On the opposite side, the picture below highlights sectors where China dominates global production. Those sectors have not been kind for global companies because profit margins have essentially disappeared. Chinese companies are choosing volume over profits, supported by Chinese banks that continue to lend to non-profitable companies at the directive of the government.
The table below shows the sectors where China will concentrate its efforts in the future. These are high-value-add sectors and the commercial clash between China and the United States will shape the global economy for the next decade.
The First Chinese Curveball to the New Trump Administration
Just as Donald Trump announced the Stargate project dedicated to huge investments in AI/data centres in the United States, performance results for DeepSeek models were released: they were truly impressive, especially considering the high-performance chips embargo that China is under and the relatively small size of the DeepSeek team. Moreover, their models are available as open source and use specialization techniques that reduce chip performance demand.
The implication is that the huge moat that supposedly encircled large current Western language models no longer looks so large. If a small firm can build highly performing models at a fraction of the cost, one can expect a race to low profitability similar to other sectors where China is competing aggressively.
American Exceptionalism
The U.S.’ brightest spot relative to China was Silicon Valley’s tech dominance. However, since ChatGPT came out in 2023, the big question has been how large language models (LLM’s) will be monetized. Just like the prospects from the Internet in the late 1990’s or those of the Chinese consumer in the early 2000’s, investors are really excited by the opportunity of LLMs and assume that Apple, Amazon, Microsoft and Google will be able to extend their existing large moats to artificial intelligence. It’s an open question whether LLMs will follow the profitability path of the Internet that eventually delivered or to the Chinese consumers that have proven disappointing.
Investor enthusiasm has led Open AI, Anthropic, Google, Meta and Microsoft to spend enormous amounts to be AI leaders. So far, their investments seem based on the motto “If you build it, they will come.” Open AI and Anthropic are dedicated to LLMs whereas Google, Meta and Microsoft aim to control the artificial intelligence ecosystem. So far, the large language model builders have adopted a brute force approach that resulted in huge demand for the best hardware. This created scarcity for Nvidia’s H100 chips (made for about $3,000 with a lifespan of 2-3 years and sold for 10 to 50 times that price). As a result, Nvidia became the most valuable company in the world.
Winners and Losers
The table below highlights our view of future market behavior in artificial intelligence. Software developers should benefit from more cost-friendly development leading to greater adoption (Jevons Paradox). Profitability winners from lower cost could be users that have not participated in the LLM arms’ race, most small businesses and everyday users. The big losers are risking being pure LLM developers like Open AI, which happens to be in fund-raising mode, and Anthropic; they could quickly become obsolete due to their high operating cost if a race to the bottom starts. Google, Microsoft and Meta have made large investments in LLM development, they are also likely losers because they have overspent but they could still benefit from greater adoption.
In terms of the infrastructure build-out, all else equal, Nvidia is a likely loser because the scarcity value of its chips will diminish, and their margins risk falling from their current stratospheric levels. Meanwhile, we expect data center enablers like energy producers and energy efficiency providers, to fare somewhat better; they will benefit from greater use of artificial intelligence but be negatively impacted by lower energy needs. Data centers will likely charge less for computing but pay less for chips. The economics behind the build-out of independent data centers (not the ones built by Google, Microsoft and Meta) generally assume a 20-year payoff. These will some under scrutiny from uncertainty in compute pricing even if the lower cost of chips could compensate for lower revenues.
The Likely Reaction
No one can “unsee” DeepSeek’s cost-to-performance results. Nonetheless, we expect a witch hunt to target the origin of their chips and intellectual property theft, leading to an eventual ban of DeepSeek in the United States.
Significance for Sustainability Investors
One of our investment themes is Productivity with Purpose, whereby technological innovations enable new solutions to improve quality of life. DeepSeek’s lower cost and energy demands could make LLMs more readily available and produce economy-wide gains as described in our note, “History Lessons for an AI Future”, June 20, 2024.
A core SMS megatrend is the age of electricity. From a pure energy efficiency standpoint, DeepSeek is an improvement over previous LLMs and could reduce the strain on projected energy demand emanating from the AI sector. However, given that AI is only a one piece of the electrification trend, we believe that the punishing market reaction to energy efficiency and nuclear power companies since Deepseek entered the scene is overdone.
DeepSeek Market Implications
The mega-cap names based in the United States have been clear beneficiaries of globalization. Their domination has grown since 2023 from the expected moats of artificial intelligence and investors assumed that the largest companies would be the ultimate beneficiaries, but a small company like DeepSeek should create doubts about their continued domination. Just like with the Internet around Year 2000, the ultimate winners have not been the ones people expected. From this standpoint, we expect subpar performance from the large companies that have optimistic implied expectations and outperformance from smaller companies that have reasonable implied expectations that will benefit from low-cost AI solutions.
Immediate Investment Opportunities in Electrification
The table below shows five companies that have fallen between 10-20% since the DeepSeek moment. Considering the long-term electrification trend should continue (even if data centers construction slows down), the activities in which they are involved will see sustained demand.
Emergence of AI Applications
As discussed above, the emergence of DeepSeek marks a shift in AI’s evolution; suddenly the technology is significantly cheaper and more efficient - if the data holds true. Moreover, as an open-source AI model, broad accessibility will facilitate further development. Based on these factors, we believe investors should shift their focus on software rather than hardware. Lower costs and improved accessibility create tailwinds for companies leveraging AI in their products.
From a sustainability perspective, we focus on AI applications that drive meaningful productivity gains (SMS theme Productivity with Purpose). Two areas with the most impactful opportunities are industrial and healthcare applications.
In industrial settings, AI enhances resource efficiency, reducing waste through optimized processes or improved design in the case of engineering tools. We have explored this topic in past research: “Finding Real Returns in Artificial Intelligence”, April 27, 2023. These companies stand to benefit not only from effective use of AI, but also from the ongoing deglobalization trend leading to new factory construction. Autodesk, PTC Inc. and Parker Hannifin are well positioned in this space and experienced strong stock performance in the past year. Dassault Systemes and Rockwell have lagged their respective peers.
In healthcare, AI is being used to improve diagnostics and accelerate drug discovery. In contrast to some of the industrial plays, healthcare names have underperformed the market in recent months offering a more attractive entry point. Both GE Healthcare and Quest Diagnostics are leveraging AI in their diagnostic tools and processes; Quest Diagnostics is also notable for its acquisition of PathAI. On the drug discovery side, Eli Lilly had partnered with OpenAI to find treatments for drug-resistant bacteria and GSK is touting the benefits of its AI use. Investors should also watch life science companies like Danaher, Agilent and Thermo Fisher, which provide tools that support drug development and research. These too can benefit from cheaper, more readily available AI.
Beyond industrial and healthcare applications, greater AI accessibility will be disruptive across other sectors, though the societal benefit varies. AI enhancements to tools like Workday, Shopify and Duolingo are beneficial, but less transformational. A step further, companies like Verisk (insurance), Wisetech Global (logistics) and Wolters Kluwer (finance, ESG) can leverage AI for specialized applications in more critical industries. However, the most significant beneficiaries of expanding AI adoption are enablers like Accenture, CGI Inc and Capgemini which help businesses across a broad range of sectors integrate AI to enhance operational efficiency and better decision-making. As this technology becomes more accessible and cost-effective, demand for their services will surely rise.
President Trump has been very clear about his ambitions to flood the world with cheap, U.S. fossil fuels. The new administration pins these goals on a desire to bring down consumer price inflation and to avoid an electricity shortage in the years ahead. Meanwhile, the natural gas industry has seized the moment, with a flurry of new deals and activity, and with little regard to climate change mitigation.
Despite the plethora of renewable energy solutions available, the new U.S. Administration has opted for drilling. In today’s Note, we explore the natural gas market in a series of questions and answers that are top of mind for sustainability investors.
1. What is behind Trump’s “drill, baby, drill” mantra?
The move to declare a national “energy” emergency appears to have three motives: to reduce consumer energy prices, improve national security and to decrease the trade deficit. Indeed, in his January 20 speech, Trump declared “…We will bring prices down, fill our strategic reserves up again right to the top, and export American energy all over the world“.
The ability to reach any of these objectives is shaky:
- On prices: The main challenge to more production of natural gas (and oil) is not red tape, it is low prices.
Survey data of U.S. gas producers show that a price of $3.69 /Million Btu is needed for producers to be profitable, but they also expect average prices to be below that level for the next two years. No wonder producers report having little intention to increase activity over the next few quarters! Since the U.S. gas market is already oversupplied, drilling is unlikely to accelerate and there is no reason to suggest natural gas prices will fall (or rise for that matter) significantly from here. Only once new sources of demand, i.e. new gas power plants come on-line, will there be a need for further drilling. That development is still years away.
- On national security: Trump’s desire to replenish reserves is related to oil - not natural gas – but it is a moot point. First, Biden began purchasing oil for replenishing the Strategic Petroleum Reserves (SPR) in August, but with delivery in February – May 2025. This means that regardless of Trump’s rhetoric, actions are already in place that will ensure an increase in the SPR in the coming months. Second, and more importantly, the SPR was created in the 1970s when the U.S. was heavily dependent on imported oil. But the U.S. is now a net exporter of oil and natural gas, with low energy dependence on other nations. Thus, “drill, baby, drill” is hardly a remedy to U.S. national security concerns since energy dependency is already less of an issue.
- On trade deficits: The U.S. is among the five nations with the most proven natural gas reserves. Not all of this gas is economic to produce and many experts believe that despite technological efficiencies, declining prime acreage and reservoir limits means that shale production growth is approaching a peak. That said, the consensus is that the U.S. has plenty of gas to export and this could help the U.S. reduce its overall trade deficit. Of course, general rules of supply and demand still apply: if there is more demand for U.S. natural gas relative to supply, prices will go up…and therefore hinder the first objective of lowering consumer energy prices!
2. Does the U.S. “need” more energy?
Total energy consumption in the U.S. has been stagnant over the past decade and the U.S. Energy Information Administration (EIA) expects this to be the case over the next decade, with increased industrial consumption to be largely offset by a decline in transportation usage.
However, this masks an important trend in what kind of energy will be in demand. By far, the most important development in energy markets is the inflection point in electricity demand. To be sure, AI and data centers have triggered new interest in electricity grids, but it is not the primary driver behind the surge in electricity demand. As the chart below shows, electricity consumption has been rising since the beginning of the decade, well before ChatGPT became a household name.
Therefore, though the U.S. may not need more total energy, it will most definitely require more electricity (and transmission). We have written about this theme in several recent notes.
What may change in 2025 is the fuel mix to generate this electricity. In a Trump world, will more electricity be generated from non-renewable sources than was forecast to be the case with the Inflation Reduction Act in place? Possibly, but it is economics that will ultimately be the deciding factor (see question four below).
3. Why such a big push for LNG and can it succeed?
One of the main reasons why the previous administration halted LNG permits is because liquefied natural gas is thought to generate even more greenhouse gases than coal (because the methane in natural gas is twenty times more potent than carbon).
However, since the current administration does not factor environmental harm into policy decisions, there is a clear line leading to exporting more LNG. As highlighted above, one of the current administration’s primary goals is to reduce the U.S. trade deficit. This requires either importing less (perhaps to be helped along by punitive import tariffs) or to export more. The U.S. energy sector is one area that has the capacity to send more overseas, particularly natural gas, by liquifying it and then transporting by sea.
Now that the building of LNG ports can be fast-tracked, there will be the capacity for LNG exports to double by 2028, should there be sufficient demand. And therein lies the rub: currently, the majority of U.S. LNG is shipped to Europe, but these countries are forecast to consume less natural gas over the next decade. To be sure, the U.S. can replace some Russian LNG, but investors should stay cognizant of the longer term trend to lower gas consumption in Europe. The U.S. may find clients in Asia, where switching from coal to gas plants remains in full swing. That said, energy security and autonomy is also a policy goal in China, making U.S. LNG less tempting in the current environment.
The bottom line is that discarding “red tape” only removes one hurdle for LNG exporters; aggressive environmental objectives in Europe as well as the geopolitics of energy security are two others that might be harder to overcome.
4. Is there any positive environmental merit to natural gas?
Natural gas is often thought of as a “bridge” fuel within the energy transition to renewables. On the surface, it’s not hard to see why, since natural gas does not share the “shortcomings” of most renewables – intermittency and lack of storability. Meanwhile, although CO2 emissions are astronomical relative to renewables, they’re nonetheless lower for dry natural gas than coal and oil.
In fact, if the U.S. electricity sector has had any success at all at reducing carbon emissions, it has been primarily through the switch from coal to natural gas (and solar and wind). But with coal now less than 20% of total fuel source for U.S. electricity, much of the “easy” reduction in emissions has already occurred.
Moreover, the “bridge fuel” argument that favors natural gas is becoming weaker over time.
As noted in the chart below, the economics of renewable energy + battery storage (excluding subsidies) are more favorable than natural gas. In other words, by combining clean technologies, one can deliver equally reliable, cheaper, and cleaner energy to the grid than through natural gas. In our note published last November, “What’s in Store for Energy Storage?” we provided an update on the advanced state of battery storage, with a focus on utility-scale solutions and the companies that are winning in this field.
In addition, it currently takes less time to build renewable plants than it does coal-fired!
5. What is a sustainable investor to do?
Natural gas has become a hot topic thanks to Trump’s energy mantra and the hype around AI’s insatiable energy needs (Deepseek notwithstanding). Indeed, there have been a flurry of high-profile announcements of both acquisitions and new gas plant construction in recent days, most of which from companies that we typically look to short sell (for example, Chevron has partnered to build new gas plants, but carbon capture installations are absent). This has not gone unnoticed by investors; even interest in the futures market has increased since Trump was elected.
With North American gas prices expected to remain depressed and at the low end of where producers are profitable, we expect tactical opportunities to short-sell U.S. gas producers.
On the long side, long-time readers will note that our preferred investment strategy to play the electrification trend is to favor companies involved in the grid buildout. We see significant opportunities across several sub-sectors critical to electrification and grid modernization: cables, substation equipment, and transmission infrastructure.
In cables, we favor Nexans (NEX FP) and Prysmian (PRY IM), both of which are global leaders in providing the essential wiring and connectivity solutions required for grid expansion. In the substation equipment segment, there are no surprises that ABB Ltd (ABBN SW) and Schneider Electric (SU FP) are favored winners, since both firms have a strong track record of innovation and are delivering equipment necessary to support smarter, more efficient energy distribution. Finally, in transmission infrastructure, we’re bullish on Valmont Industries (VMI US) and Stella-Jones Inc (SJ CN), both of which provide essential transmission and utility poles and towers.
Note that many of these companies received a severe knock earlier this week with the news that Deepseek, China’s opensource large language models, consume far less energy to deliver the same results. However, as mentioned above, the electrification trend goes well beyond artificial intelligence needs; today’s lower entry points make many of our preferred names even more attractive.
To convince yourself that six months can fundamentally reshape market narratives, look no further than the dramatic reversals in political consensus or the stark trajectories of pharmaceutical giants Novo Nordisk and Eli Lilly. The meteoric rise and subsequent recalibration of GLP-1 drugmakers’ valuations offer a compelling case study in market psychology and pharmaceutical sector dynamics. Much like NVIDIA’s AI-driven surge, investors initially viewed obesity treatment approvals as an inflection point that would propel these companies into sustained upward trajectories. However, the narrative has proven more complex, with Novo Nordisk’s stock retreating 45% from its summer 2024 peak and Eli Lilly declining 25% from its highs. This correction reflects a market coming to terms with the practical challenges of scaling revolutionary treatments. In this note, we examine the factors behind this shift in sentiment, analyze the operational and market hurdles facing the industry, and explore emerging opportunities in the evolving GLP-1 landscape.

The recent pullback in obesity drug stocks can be attributed to several key factors, but primarily centers around access and pricing challenges. Since 2021, there has been a meteoric rise in the adoption of GLP-1 drugs: semaglutide prescriptions in the U.S. jumped from about 2 million adults in 2021 to an estimated 15 million in 2024, representing over 10% of eligible patients. However, this rapid growth has begun to face headwinds in penetrating the remaining addressable market, largely due to insurance coverage constraints.
In the U.S., insurance coverage remains fragmented and restrictive:
- Many Affordable Care Act (ACA) Marketplace plans limit GLP-1 coverage to diabetes treatment, thereby excluding weight loss applications.
- Other major private insurers like Independence Blue Cross have withdrawn obesity treatment coverage, citing cost concerns.
- For low-income individuals relying on Medicaid (over 1 in 5 Americans), coverage is expanding gradually, with North and South Carolina recently joining a dozen other states in covering obesity treatments.
- Coverage through Medicare (federal health insurance for those over 65) is pending, with Biden’s November 2024 proposal for expanded coverage now in limbo under the Trump administration.
The political landscape adds another layer of uncertainty. Robert F. Kennedy Jr., Trump’s nominee for Health and Human Services Secretary, has historically criticized weight-loss medications, arguing they create dependency rather than addressing root dietary issues. However, his recent statements suggest a potential softening of this stance, acknowledging GLP-1s’ role in chronic condition management and indicating openness to selective coverage.
Further complicating the outlook, Ozempic and Wegovy’s inclusion in the IRA’s drug price negotiation program could substantially impact U.S. pricing of these drugs. Pricing disparities are evident internationally: monthly Wegovy prescriptions cost $140 in Germany and $92 in the UK, versus $1,349 in the U.S. This gap highlights the potential magnitude of price adjustment under government negotiations, similar to what we observed in the insulin market (as detailed in our note (“Basic Instinct: The Insulin Profit Machine”, September 22, 2023).
The competitive landscape is also evolving rapidly. While Novo Nordisk and Eli Lilly command a formidable first-mover advantage, their competitors are aggressively accelerating development programs to capture share in this lucrative market. The battleground is increasingly centered on accessibility and affordability, with particular emphasis on oral formulations that could dramatically expand the addressable market (current GLP-1 medicines are administered by injection). Several promising candidates are emerging.
Market leadership appears secure in the near term, with Novo Nordisk and Eli Lilly commanding nearly half of the industry's development pipeline. The competitive moat is substantial: major pharmaceutical companies like Roche, Pfizer, AstraZeneca, and Amgen lag several years behind, with meaningful competition unlikely before 2028/2029 once accounting for commercial-scale manufacturing ramp-up.
The most compelling competitive threat is Structure Therapeutics (GPCR US). Their oral GLP-1 candidate has demonstrated promising early results and, while still 12-24 months from potential commercialization, represents the most advanced oral formulation in development. Their progress warrants close monitoring as oral administration could revolutionize market dynamics.
Patent expiration presents another frequently cited risk, though the timeline suggests limited near-term impact:
- Novo Nordisk's U.S. patents for Ozempic and Wegovy extend to 2032;
- Earlier patent expiration in markets like China could see first-generation generics by 2026;
- Eli Lilly's Mounjaro maintains exclusivity until approximately 2036;
- Both companies have strategically secured patent term extensions.
However, the complexity of manufacturing GLP-1 drugs provides an additional barrier to generic competition. Unlike small molecule drugs, biologics, which are developed from living organisms, require sophisticated production capabilities that few manufacturers possess. This complexity, combined with the extensive regulatory requirements for biosimilars, suggests that generic competition may evolve more gradually than historical pharmaceutical patent cliffs would indicate.
Despite these challenges, forecasts suggest the weight-loss drug market is poised for exponential growth—fueled by rising demand, expanding applications, and continued innovation.
The transformative potential of GLP-1 drugs extends far beyond obesity treatment. Recent clinical evidence suggests these compounds may revolutionize the treatment of various addictive behaviors by modulating reward pathways in the brain. Their ability to curb food cravings appears transferable to other dependencies, including tobacco, alcohol, and even opioids, opening entirely new therapeutic frontiers.
Perhaps most intriguingly, emerging research indicates promising applications in neurodegenerative conditions, particularly Alzheimer's disease. The connection lies in the brain's glucose metabolism—a critical factor in cognitive function that becomes impaired in Alzheimer's patients. GLP-1 drugs' ability to regulate glucose metabolism could potentially slow or alter disease progression, representing a novel approach to this devastating condition.
The recent market correction in Novo Nordisk and Eli Lilly shares appears overdone, presenting a compelling entry point into what we believe is still the early innings of a transformative healthcare trend. Both companies have demonstrated their ability to develop and commercialize life-changing medications, and their current valuation post-correction offers a more attractive risk-reward proposition.
While we maintain high conviction in both companies' leadership positions—earned through pioneering innovation and sustained by significant R&D investment—investors seeking broader exposure to the theme might consider diversified vehicles such as the Roundhill GLP-1 & Weight Loss ETF (OZEM US).